Combination Therapy Reduces Colon Cancer Risk

Article

Sulindac and erlotinib effectively reduced the total duodenal polyps in patients with familial adenomatous polyposis.

A combination drug therapy was found to reduce polyps in patients with familial adenomatous polyposis (FAP), who are more susceptible to developing colorectal cancer.

A study published in JAMA enrolled 92 patients with FAP. Patients were randomly assigned to receive both sulindac twice daily and erlotinib daily (n=46) or placebo (n=46) for 6 months.

The results of the study showed that the combination of sulindac and erlotinib were able to effectively reduce the total duodenal polyps and the polyp number in participants compared with placebo. The effect was most significant after 6 months of therapy.

Adverse events were graded 1 and 2 in severity and were more common in the sulindac-erlotinib group.

Eighty-seven percent of patients who received treatment developed an acne-like rash and 20% in the placebo group. Researchers believe that these adverse events could limit the use of sulindac and erlotinib.

“Further research is necessary to evaluate these preliminary findings in a larger study population with longer follow-up to determine whether the observed effects will result in improved clinical outcomes,” the authors wrote.

Related Videos
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com
Image Credit: © Anastasiia - stock.adobe.com
LGBTQIA+ pride -- Image credit: lazyllama | stock.adobe.com
Image Credit: © Анастасія Стягайло - stock.adobe.com
breast cancer treatment/Image Credit: © Siam - stock.adobe.com
Image Credit: © Dragana Gordic - stock.adobe.com
small cell lung cancer treatment/Image Credit: © CraftyImago - stock.adobe.com
lymphoma, OPC, ASCO 2024, hodgkin lymphoma
© 2024 MJH Life Sciences

All rights reserved.